Kamil Ali-Jackson - 06 May 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
06 May 2021
Net transactions value
-$261,210
Form type
4
Filing time
07 May 2021, 18:28:02 UTC
Previous filing
22 Nov 2021
Next filing
02 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $159,900 +15,000 +10% $10.66 158,618 06 May 2021 Direct
transaction ACRS Common Stock Sale $277,438 -11,898 -7.5% $23.32 146,720 06 May 2021 Direct F1, F2
transaction ACRS Common Stock Sale $74,016 -3,102 -2.1% $23.86 143,618 06 May 2021 Direct F1, F3
transaction ACRS Common Stock Options Exercise $57,735 +5,416 +3.8% $10.66 149,034 07 May 2021 Direct
transaction ACRS Common Stock Sale $77,016 -3,316 -2.2% $23.23 145,718 07 May 2021 Direct F1, F4
transaction ACRS Common Stock Sale $50,376 -2,100 -1.4% $23.99 143,618 07 May 2021 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (Right to Buy) Options Exercise $0 -15,000 -73% $0.000000 5,416 06 May 2021 Common Stock 20,416 $10.66 Direct F6
transaction ACRS Employee Stock Option (Right to Buy) Options Exercise $0 -5,416 -100% $0.000000* 0 07 May 2021 Common Stock 5,416 $10.66 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.79 to $23.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.83 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.83 to $24.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The option is fully vested.